Valion Bio (VBIO) Intangibles (2025 - 2026)
Valion Bio (VBIO) posted Intangibles of $2.2 million for Q2 2026, little changed on a QoQ basis from $2.2 million in Q4 2025.
Analysis
Valion Bio (VBIO) Intangibles (2025 - 2026) Analysis & Trends
Valion Bio has reported Intangibles for 2 years, with the latest figure at $2.2 million in Q2 2026.
- On a quarterly basis, Intangibles changed N/A year-over-year to $2.2 million in Q2 2026; TTM through Jun 2026 was $2.2 million, a N/A change from a year earlier, with the FY2025 full-year figure at $2.2 million, changed N/A from the prior year.
- Intangibles was $2.2 million for Q2 2026 at Valion Bio, roughly flat from $2.2 million in the prior quarter.
- The five-year high for Intangibles was $2.2 million in Q3 2025, with the low at $2.2 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 20.49 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 14.03 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 412.80 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 1.31 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 266.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 13.52 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Valion Bio | 298,792.01 | -1.90 Mn | -45,000.00 | 2.24 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.24 Mn |
| Dec 31, 2025 | 2.24 Mn |
| Sep 30, 2025 | 2.24 Mn |